Athersys and Angiotech announce authorization of stem cell clinical trial

VANCOUVER - Co-developers Athersys Inc. and Angiotech Pharmaceuticals Inc. (TSX:ANP) say they have received authorization from the U.S. Food and Drug Administration to begin clinical trials of a stem cell-based treatment for heart attacks....More